|
Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study Clinical research trials and Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study. Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study  Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study
Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study
For Condition: Hypertrophic Cardiomyopathy
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: This study will test the feasibility of a modified procedure for treating obstructive hypertrophic cardiomyopathy (OHC). Patients with OHC have a thickening of the heart muscle that obstructs blood flow out of the heart, causing breathlessness, chest pain, palpitations, tiredness, lightheadedness, and fainting. The current treatment for OHC is a procedure called alcohol septal ablation (also percutaneous transluminal septal ablation, or PTSA), which involves injecting a small amount of alcohol into a tiny artery that supplies the part of muscle causing blood flow obstruction. The success of PTSA is limited, however, by problems of heart anatomy and the ability to find the appropriate artery to inject. Modifying the procedure by injecting the alcohol through the wall of the lower right chamber of the heart may improve its safety and effectiveness. The new technique requires positioning a catheter (a flexible tube) into the appropriate area of the heart. This study will test the ability to accurately guide the catheter to that area. Patients with OHC 18 years of age and older who are scheduled to have a cardiac catheterization may be eligible for this study. At the end of the catheterization procedure, participants will undergo intra-cardiac echocardiographic imaging. For this test, one of the catheters placed in the femoral artery (at the top of the leg) for cardiac catheterization will be substituted for a larger one. Through this catheter, a special catheter will be introduced and advanced to the heart to provide images. This pilot feasibility study does not involve injection of alcohol.
Details: Patients with obstructive hypertrophic cardiomyopathy (HCM) and drug-refractory symptoms have traditionally been referred for cardiac surgery to widen the left ventricular (LV) outflow tract. More recently, percutaneous transluminal septal ablation (PTSA) has also been shown to thin the subvalvular septum and thereby to reduce LV outflow pressure gradients and to improve symptoms in obstructive HCM. However, this procedure is not infrequently limited by septal coronary artery anatomy and inability to identify and cannulate the appropriate artery that supplies the septal region of interest. Some attempts are also associated with coronary artery dissection, particularly, if there is associated coronary artery disease. A trans-right ventricular (RV) alcohol septal ablation (TRVASA) would significantly simplify the procedure, and increase its safety. The purpose of this study is to initially test our ability to visualize and guide a delivery catheter to a targeted part of the anterior interventricular septum involved in the generation of the LV outflow obstruction using intracardiac echocardiography (ICE). No therapy is intended: alcohol will not be injected into the septum in this initial study.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Patients of either gender, aged 18-85 years. Symptomatic patients receiving clinically indicated evaluation for cardiomyopathy and found to have obstructive HCM. LV outflow tract gradient greater than 30 mm Hg at rest by echocardiography or cardiac catheterization. EXCLUSION CRITERIA: Positive pregnancy test.
Total Enrollment: 12
Location and Contact Information:
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 020125; 02-H-0125
Study Start Date: April 24, 2002
Record last reviewed: April 8, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035386
Other Hypertrophic Cardiomyopathy Studies:
1. Factors Contributing to Increased Left Ventricle Size in Patients with Abnormally Enlarged Hearts
2. Investigation into the Use of Ultrasound Technique in the Evaluation of Heart Disease
3. Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children with Obstructive Hypertrophic Cardiomyopathy (HCM)
4. Studying the Effectiveness of Pacemaker Therapy in Children who Have Thickened Heart Muscle
5. Screening for Inherited Heart Disease
Related Studies:
Other Hypertrophic Cardiomyopathy Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study
|
|
|
|
|
|
|
|
